An open-label, phase I pilot study conducted by Hirschowitz EA et al. investigated the effects of a vaccine named 1650-G, which incorporates a tumor-associated antigen DC vaccine alongside GM-CSF. This evidence concerns the gene CSF2 and neoplasm.